FDA grants orphan drug designation for devimistat for biliary cancer
Devimistat is a lipoate analog, targeting the mitochondrial tricarboxylic acid cycle. It also has orphan status in the US for pancreatic cancer, acute myeloid leukaemia, myelodysplastic syndrome, peripheral T-cell lymphoma, soft tissue sarcoma, and Burkitt’s lymphoma.
Source:
Biospace Inc.